• FirefoxInstall the new Firefox »
  •  Dow Down0.45% Nasdaq Down0.49%

    Heron Therapeutics, Inc. (HRTX)

    12.99 Up 0.41(3.26%) Feb 27, 4:00PM EST
    |After Hours : 12.98 Down 0.01 (0.04%) Feb 27, 4:36PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Heron Therapeutics, Inc.
    123 Saginaw Drive
    Redwood City, CA 94063
    United States - Map
    Phone: 650-366-2626
    Website: http://www.herontx.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:47

    Business Summary 

    Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform. The company's drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. Its lead product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. The company's product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Heron Therapeutics, Inc.

    Corporate Governance 
    Heron Therapeutics, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Barry D. Quart Pharm.D., 58
    Chief Exec. Officer and Director
    Mr. Robert H. Rosen , 59
    Pres and Director
    Mr. Brian G. Drazba CPA, 54
    Chief Financial Officer and VP of Fin.
    Mr. Paul G. Marshall , 55
    Sr. VP of Technical Operations
    Ms. Esmé C. Smith J.D.,
    VP, Gen. Counsel and Sec.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders